Spotlight on Oculogyric Crisis: A Review

Pankaj Mahal1, Navratan Suthar2, Naresh Nebhinani1

ABSTRACT

Background: Oculogyric crisis (OGC) is a form of acute dystonia characterized by sustained dystonic, conjugate, and upward deviation of the eyes. It was initially reported in patients with postencephalitic parkinsonism. But later, other factors such as medications, movement disorders, metabolic disorders, and focal brain lesions were also found to be associated with OGC.

Methods: The literature regarding OGC was searched via PubMed, Google Scholar, and through citations in relevant articles till December 2019, with keywords including OGC, oculogyric eye movements, tonic eye movement, neuroleptics and OGC, antipsychotics and OGC, and all combinations of these. Only original articles (abstract or full text) that were published in the English language were reviewed.

Results: Hypodopaminergic state is implicated in the pathogenesis of OGC. Common risk factors are younger age, male sex, severe illness, high neuroleptic dose, parenteral administration of neuroleptics, high potency of neuroleptic drugs, abrupt discontinuation of anticholinergic medication, and family history of dystonia.

Conclusion: OGC is an acute dystonic reaction leading to tonic upward deviation of eyes. It is associated with various neurometabolic, neurodegenerative, and movement disorders and medications such as antipsychotics, antiemetics, antidepressants, antiepileptics, and antimalarials. OGC can adversely impact the compliance and prognosis of the primary illness. Hence, it needs to be managed at earlier stages with appropriate medication, primarily anticholinergics.

Keywords: OGC, oculogyric crisis, blepharospasm, acute dystonia

Key Message: Practitioners must know the common risk factors and etiopathogenesis of OGC. It would help them in choosing appropriate medication as well as timely identification and management.

Oculogyric Crisis (OGC) is a form of dystonic movement disorder characterized by paroxysmal, conjugate, and typically upward deviation of the eyeball, which occurs for seconds to hours.1,2 Onset of OGC is generally acute, but sometimes it may develop after a few weeks or months of a precipitating event. Additionally, the patient may have increased blinking of the eyes, neck dystonia, tongue protrusion, blepharospasm, and autonomic signs such as perspiration, increased blood pressure, tachycardia, pupillary dilation, facial flushing, salivation, and difficulty in micturition.3–5 Psychiatric symptoms such as anxiety, visual hallucinations or illusions, auditory hallucinations, catatonic phenomena, transitory delusions, or obsessive ideas may also accompany an OGC experience.6

Besides antipsychotics, other medications such as antiemetics, antidepressants, antiepileptics, and antimalarials are also associated with OGC.4 It is also seen with various genetic or metabolic disorders that affect dopamine production, storage, or reuptake. The exact incidence of OGC is currently unknown, though one study reported it to be around 5.3%,6,8 whereas the incidence of OGC with antipsychotics is in the range 0.9%-3.4%.7 It is important to distinguish OGC from other similar presenting conditions such as epileptic seizures, paroxysmal tonic upgaze syndrome, or oculogyric tics.8–10 In this review, we provide an overview of the various causes, risk factors, pathophysiology, diagnosis, differentials/mimickers, and management of OGC.

Materials and Methods

The literature regarding OGC was searched via PubMed and Google Scholar and through citations in relevant articles till December 2019, with keywords including OGC oculogyric eye movements, tonic eye movement, neuroleptics and OGC, antipsychotics and OGC, and various combinations of these. An
addition search was performed for specific topics under this review. Only original articles (abstract or full text) that were published in the English language were reviewed. More than 200 articles related to the topic were found, out of which the articles relevant to psychiatry are primarily included here. Most of the publications related to OGC are either case reports or case series. In this review, we have focused on the adult population with OGC and its association with psychiatric symptoms/diagnosis.

Results

Etiology of OGC

Though the exact pathogenesis of OGC is not certain, various factors that contribute to its occurrence have been reported.

OGC is seen with different kinds of movement disorders such as tongue protrusion, lip-smacking, blepharospasm, choreoathetosis, anterocollis, and retrocollis. Various neurological disorders are also found to be associated with OGC, such as Parkinson’s disease, familial Parkinson’s–dementia syndrome, dopa-responsive dystonia, parkinsonism with basal ganglia calcifications (Fahr’s disease), neurosyphilis, multiple sclerosis, ataxia–telangiectasia, Wilson disease, and acute herpetic brain-stem encephalitis.

Various genetic, neurometabolic disorders also play a part in the etiology of OGC. Hereditary dopamine transporter deficiency syndrome, in which, due to novel homozygous SLC6A3 gene mutations, there would be orolingual dyskinesia, Wilson disease, and acute herpetic brain-stem encephalitis.

Some neurodegenerative disorders are also found to be associated with the occurrence of OGC, such as mutations in the DRD3 gene, which affects the function of both N-methyl-D-aspartate and dopamine D3 receptors, leading to oculomotor dystonic reactions. Neuronal intranuclear hyaline inclusion disease, a multisystem degenerative disorder that involves both central and peripheral nervous systems, causing diffuse muscle spasms, dystonia, dysphagia, tremors, ataxia, OGC, progressive muscle weakness, and atrophy; Rett syndrome, progressive neurodegenerative disorder in females, leads to gait disturbance, bruxism, OGC, parkinsonism, and dystonia and tyrosine hydroxylase (TOH) deficiency, an inborn error of catecholamine biosynthesis causing dystonia along with tremor, hypersensitivity to levodopa therapy, OGC, akinesia, and rigidity. Other autosomal recessive disorders that rarely present with OGC are Kufor Rakeb, haemophagocytic lymphohistiocytosis, sepiapterin reductase deficiency, and GTP cyclohydrolase I deficiency.

Some brain lesions are also associated with OGC, such as lesions in periaqueductal and midbrain tegmentum, brainstem, or substantia nigra and cystic glioma in the region of the posterior third ventricle.

Finally, medications which would increase the risk of developing OGC include various groups such as antipsychotics, antiemetics, anticonvulsants, and antidepressants (Table 1). Acute dystonic reactions are commonly seen with the use of high-potency typical antipsychotics, relatively uncommon with atypical antipsychotics, and rarely reported with clozapine. A few cases of acute dystonic reaction, including OGC, have been associated with anesthetic agents like propofol, sevoflurane, nitrous oxide, and fentanyl administration.

In recent times, most of the literature is associated with varied causes of OGC belonging to either neurometabolic disorders such as AADC deficiency, sepiapterin reductase deficiency, TUBB4A-related leukodystrophy or medications (apart from what mentioned in Table 1) like anti-tubercular drugs, clebopride, a non-selective benzamide with antidopaminergic activity.

Mechanism of OGC

The exact mechanism of OGC is not clear. Most of the brain lesions that lead to OGC are found in the nigrostriatal pathway. Besides, several hypotheses have been given for drug-induced OGC such as striatal cholinergic hyperactivity, striatal dopaminergic hypoaactivity (commonly reported), or the rarely reported striatal dopaminergic hyperactivity. The majority of the conditions are related to dopaminergic dysfunction, including disorders of dopamine metabolism leading to low dopamine levels, such as TOH deficiency and AADC deficiency.

### Table 1

| Drugs Classification | Drugs |
|----------------------|-------|
| First-generation antipsychotics (FGA) | Haloperidol, Fluphenazine, Flupentixol, Perphenazine, Chlorpromazine, Zuclupenthixol |
| Second-generation antipsychotics (SGA) | Risperidone, Aminosulpride, Aripiprazole, Olanzapine, Quetiapine, Clozapine, Ziprasidone, Lurasidone |
| Antidepressants | Imipramine, Escitalopram, Fluvoxamine |
| Anticonvulsants | Carbamazepine, Lamotrigine, Gabapentin |
An imbalance between dopaminergic and cholinergic neurotransmission in the striatum has also been proposed for drug-induced OGC.45

Hypersensitivity of striatal dopamine receptors due to chronic dopamine receptor blockade, neurodegeneration of striatal interneurons, dysfunction of striatal gamma-aminobutyric acid (GABA)-ergic interneurons, or maladaptive synaptic plasticity are reported to be the causes of tardive involuntary movements.46 Antidepressants-induced OGC is explained with hyperstimulation of 5-HT2 receptors, inhibition of dopaminergic activity, and alteration of cholinergic and GABAergic activity.47

Risk Factors of OGC

Certain characteristics of patients would make them more vulnerable for the emergence of OGC, such as younger age,48,49 male sex,50 greater severity of illness,49 greater baseline psychopathology,50 increasing neuroleptic dose,48 parenteral administration of neuroleptics,51 high potency of neuroleptic drugs,52 abrupt discontinuation of anticholinergic medication within the first few weeks of initiating neuroleptics,53 metabolic conditions (e.g., hypocalcemia, hyperthyroidism, hyperparathyroidism),54 recent cocaine use,51 and family history of dystonia.44

Diagnosis of OGC

Diagnosis of OGC is clinical, based on typical symptoms such as paroxysmal, conjugate, and typically upward deviation of the eyeball for seconds to hours. Slow et al. has proposed the required and supportive criteria for diagnosing OGC (Table 2). Whenever clinicians encounter an OGC-like phenomenon, they should approach in a manner as suggested in Figure 1.

Differential Diagnosis/ Mimickers of OGC

Several clinical entities look similar to OGC. Therefore, meticulous history and thorough clinical examination should be done for differentiating other phenomena from OGC (Table 3).

Management of OGC

The mainstay of treatment of OGC is based on its etiology.4 In the case of drug-induced OGC (e.g., antipsychotics), generally, the first approach is to taper down the causative drug. On the persistence of OGC on reducing the dose, discontinuation of the offending agent is advised, with shifting to other agents with a lesser propensity to cause dystonic reactions.45,55

For the management of cases where the mentioned strategy would not cause improvement, other pharmacological management options should be tried. In OGC, primarily anticholinergics such as trihexyphenidyl, benztropine, benzhexol, biperiden, procyclidine, or other centrally acting anticholinergic drugs or antihistaminergic agents (e.g., diphenhydramine, phenhydramine, chlorpheniramine, promethazine) are commonly used.51 In most cases of acute dystonic reactions, the intravenous route is the preferred route of choice as it leads to improvement within 10 minutes. Alternatively, intramuscular (if you cannot access intravenous line) or oral (most unreliable, due to extensive gut first-pass metabolism) route can be used.54 Sometimes benzodiazepines and rarely dopamine agonists are also used.51 To avoid recurrence, it is recommended to continue the management of OGC for at least a week but sometimes for longer periods in case of tardive OGC. If the above line of treatment fails, then clozapine remains a promising option as it works via the stimulation of M4 muscarinic receptors, which results in inhibition of D1 receptors or the direct blockade of D1 receptors.45 But rarely, in some cases, OGC has been reported with the use of clozapine.51 Electro-convulsive therapy can also be given in tardive OGC cases with psychiatric disorders.35

Prophylactic use of anticholinergic drugs for 1–2 weeks is indicated in patients with greater vulnerability for OGC with certain antipsychotics, though the available guidelines are inconsistent for the duration of use of such prophylactic agents.56 Levodopa may be useful in Parkinson’s disease with OGC. Anticholinergics are also found to be beneficial in OGC associated with focal brain lesions.

The dystonic reactions are associated with considerable physical and psychosocial consequences such as increased psychiatric comorbidity,49 poor compli-

### Table 2

| Proposed Criteria for the Diagnosis of Oculogyric Crisis*43 |
|----------------------------------------------------------|
| **Required Criteria**                                    |
| • Tonic, conjugate deviation of eyes                     |
| • Minutes to hours in duration                           |
| • Consciousness preserved                                |
| **Supportive Criteria**                                  |
| • Preceded by anxiety, discomfort                        |
| • The patient is aware of and bothered or disabled by the ocular deviations |
| • Associated dystonia                                    |
| • Associated with a low dopamine state and improved by anticholinergics or dopaminergic medication |

### Figure 1

**Approach to a Patient with OGC-Like Phenomenon**

1. Presence of possible OGC (confirmation with meticulous history and thorough examination)
2. Rule out the possible mimickers (epileptic seizures, paroxysmal tonic upgaze syndrome or oculogyric tics, psychogenic movements)
3. Rule out the possible medications
4. Rule out the other genetic/metabolic/traumatic causes

OGC: Oculogyric crisis.
ance, increased fatigue, and sleep disturbances, leading to decrease quality of life. OGC and blepharospasm can significantly affect daily living activities such as driving, shaving, combing, or dressing. These effects are more pronounced with tardive dystonia cases and can even lead to social avoidance, isolation, and stigmatization. Hence, both non-motor and motor features associated with dystonia should be managed in order to improve the quality of life.

Conclusion

The timely diagnosis and early identification of the causative medication play an important role in the course and management of OGC. It can cause extreme agitation, which can mimic worsening of psychosis in psychiatric patients. Treatment of OGC is mainly causal, as its etiology is multifactorial, involving both dopaminergic and cholinergic systems. Doctors must be aware of the varied presentation of OGC, as recurrent dystonic reactions have obvious implications on medication adherence and course and prognosis of primary disorders. OGC should be managed with meticulous history, examination, serial assessments, medications, and regular follow-up.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

References

1. Solberg M and Koht J. Oculogyric crises. Tremor Hyperkinetic Mov [Internet] 2017 [cited Apr 17, 2019]; 7; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623758/ (accessed July 27 2020)
2. Barow E, Schneider SA, Bhatia KP, and Gates C. Oculogyric crises: Etiology, pathophysiology and therapeutic approaches. Parkinsonism Relat Disord 2017; 36: 3–9.
3. Abe K. Psychiatric symptoms associated with oculogyric crisis: A review of literature for the characterization of antipsychotic-induced episodes. World J Biol Psychiatry 2006; 7(2): 70–74.
4. Kohan Y, Ekinci M, Cagatay HH, and Yazlar Z. Oculogyric crisis in a patient taking metoclopramide. Clin Ophthalmol 2014; 8: 567–569.
5. Lewis K and O’Day CS. Dystonic reactions [Internet]. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2019 [cited Apr 17, 2019], http://www.ncbi.nlm.nih.gov/books/NBK531466/ (accessed July 27, 2020).
6. Spina E, Sturiale V, Valvo S, et al. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol 1993; 8(1): 21–24.
7. Gardner DM, Abidi S, Ursuila Z, et al. Incidence of oculogyric crisis and long-term outcomes with second-generation antipsychotics in a first-episode psychosis program. J Clin Psychopharmacol 2015; 35(6): 715–718.
8. Wyllie E, Lüders H, Morris HH, Lesser RP, and Dinner DS. The lateralizing significance of versive head and eye movements during epileptic seizures. Neurology 1986; 36(3): 606–611.
9. Salmina C, Taddle I, Fales M, et al. Paroxysmal tonic upgaze in normal children: A case series and a review of the literature. Eur J Paediatr Neurol 2012; 16(6): 683–687.
10. Jankovic J and Stone L. Dystonic tics in patients with Tourette’s syndrome. Mov Disord 1991; 6(3): 248–252.
11. Gold DR. Eye movement disorders: Congenital gaze abnormalities [Internet]. In: Liu GT, Volpe NJ and Galetta SL (eds) Liu, Volpe, and Galetta’s Neuro-Ophthalmology, 3rd ed. Elsevier; 2019 [cited Mar 26, 2020]; pp. 549–84, http://www.sciencedirect.com/science/article/pii/B97803233433044100016X (accessed July 27, 2020).
12. Yildiz Y, Pektas E, Tokatli A, and Haliloglu G. Hereditary dopamine transporter deficiency syndrome: Challenges in diagnosis and treatment. Neuropediatrics 2017; 48(1): 49–52.
13. Portaro S, Gugliandolo A, Scioni D, et al. When dysphoria is not a primary mental state: A case report of the role of the aromatic L-aminoacid decarboxylase. Medicine (Baltimore) 2018; 97(22): e11035.
14. Lee LK, Cheung KM, Cheng WW, et al. A rare case of severe diarrhoea diagnosed by urine metabolic screening: aromatic L-amino acid decarboxylase deficiency. Hong Kong Med J 2014; 20(2): 161–164.
15. Wennberg T, Moler-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis 2017; 12(1): 12.
16. De Giorgis V, Varesio C, Baldassari C, et al. Atypical manifestations in Glut1 deficiency syndrome. J Child Neurol 2016; 31(9): 1174–1180.
17. Jacobsen JC, Wilson C, Cunningham V, et al. Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder. J Inherit Metab Dis 2016; 39(2): 305–308.
18. Leuzzi V, Carducci CA, Carducci CL, et al. Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyltetrahydropterin synthase deficiency. Clin Genet 2010; 77(3): 249–257.
19. Almannai M, Felemban R, Saleh MA, et al. 6-Pyruvoyltetrahydropterin synthase deficiency: Review and report of 28 Arab subjects. Pediatri Neurol 2019; 98: 40–47.
20. Rohani M, Shahidi G, Vali F, et al. Oculogyric crises in PLA2G6 associated

---

**TABLE 3.**

| Differentials | Description |
|---------------|-------------|
| Seizures      | Repetitive, clonic, or tonic eye movements |
| Paroxysmal tonic upgaze | Upward eye deviation lasting seconds to hours |
| Ocular dyskinesias | Repetitive, upward gaze usually lasting only a few seconds |
| Ocular tics | Brief ocular deviations |
| Psychogenic | Distractible ocular movements and associated with other functional movements and other functional findings |

OGC: Oculogyric crisis.
neurodegeneration. Parkinsonism Relat Disord 2018; 52: 111–112.
21. Pironi E, Granata F, Cucinotta F, et al. Electroclinical history of a five-year-old girl with GRIN1-related early-onset epileptic encephalopathy: a video-case study. Epileptic Disord Int Epilepsy J Videoepilepsy 2018; 20(5): 423–427.
22. Ohba C, Shinya M, Tohyama J, et al. GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders. Epilepsia 2015; 56(6): 841–848.
23. Parker JC, Dyer ML, and Paulsen WA. Neuronal intranuclear hyaline inclusion disease associated with premature coronary atherosclerosis. J Clin Neuroophthalmol 1987; 7(4): 244–249.
24. FitzGerald PM, Jankovic J, and Percy AK. Rett syndrome and associated movement disorders. Mov Disord 1990; 5(3): 195–202.
25. Grattan-Smith PJ, Wevers RA, Steenbergen-Spanjers GC, et al. Tyrosine hydroxylation deficiency: Clinical manifestations of catecholamine insufficiency in infancy. Mov Disord 2002; 17(2): 354–359.
26. Pons R, Serrano M, Ormazabal A, et al. Tyrosine hydroxylation deficiency in three Greek patients with a common ancestral mutation. Mov Disord 2010; 25(8): 1086–1090.
27. Williams DR, Hadeed A, al-Din ASN, Wreikat A-L, and Lees AJ. Kufor Rakeb disease: Autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005; 20(10): 1264–1271.
28. Taipa R, Moreira B, França M, and Maia LF. A case of haemophagocytic syndrome presenting with oculogyric crises. J Neurol Neurosurg Psychiatry 2010; 81(4): 469–471.
29. Friedman J, Roze E, Abdenur JE, et al. Sepiapterin reductase deficiency: A treatable mimic of cerebral palsy. Ann Neurol 2012; 71(4): 520–530.
30. Koth J, Rengmark A, Opladen T, et al. Clinical and genetic studies in a family with a novel mutation in the sepiapterin reductase gene. Acta Neurol Scand Suppl 2014(198): 7–12.
31. Horvath GA, Stockler-Ipsiroglu SG, Salvizarova-Zivkovic R, et al. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: Evidence of a phenotypic continuum between dominant and recessive forms. Mol Genet Metab 2008; 94(1): 127–131.
32. Devinsky O. Neuroanatomy of Gilles de la Tourette’s syndrome: Possible midbrain involvement. Arch Neurol 1983; 40(8): 508–514.

33. Matsumura K and Sakuta M. Oculogyric crisis in acute herpetic brainstem encephalitis. J Neurol Neurosurg Psychiatry 1987; 50(3): 365–366.
34. Leea JH, Lyoob CH, Leec JG, and Leeb AL. Oculogyric crisis associated with disulfiram-induced pallidodermal lesion. J Mov Disord [Internet] [cited Apr 21, 2019], http://www.e-jmd.org/journal/view.php?number=83 (accessed July 27, 2020).
35. Heimburger RF. Positional oculogyric crises: Case report. J Neurol Neurosurg Psychiatry 1988; 69(6): 951–953.
36. Nebhinani N and Suthar N. Oculogyric crisis with atypical antipsychotics: A case series. Indian J Psychiatry 2017; 59(4): 499.
37. Nebhinani N, Avasthi A, and Modi M. Oculogyric crisis with clozapine: A case report and review of similar case reports in the literature. Indian J Psychiat Med 2015; 37(3): 342.
38. Jitrapakulsan J and Srivinitchapoom P. Acute dystonic reaction following general anesthetic agent use. Treme Hyperkinet Mov N Y N 2017; 77: 514.
39. Nahhas N, Conant A, Hamilton E, et al. TUB8A1-Related Leukodystrophy [Internet]. In: Adam MP, Arding HH, Pagon RA, et al. (ed) GeneReviews®. Seattle, WA: University of Washington, 1993 [cited Apr 24, 2020], http://www.ncbi.nlm.nih.gov/books/NBK39561/ (accessed July 27, 2020).
40. Wong LH and Tan E. Anti-tuberculosis medication-induced oculogyric crisis and the importance of proper history taking. Int Med Case Rep J 2017; 10: 341–344.
41. Choi JK and Hong JY. Acute cervical dystonia induced by clebopride. Case Rep Neurol Med 2017; 2017: 2834349.
42. Jacob S, Ly H, Villenueva RJ, and Gupta M. Acute dystonic reaction following general anesthetic agent use. Treme Hyperkinet Mov N Y N 2017; 77: 514.
43. Slow EJ and Lang AE. Oculogyric crises: Case report. J Neurosurg 1988; 69(6): 951–953.
44. Schneider SA, Udani V, Sankhla CS, and Bell EM. Oculogyric crises: Case report. J Neurosurg 1988; 69(6): 951–953.
45. Prisco S and Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Br J Pharmacol 1995; 116(2): 1923–1931.
46. Keepers GA and Casey DE. Prediction of Neuroleptic-Induced Dystonia. J Clin Psychopharmacol 1987; 7(5): 342.
47. Aguilar El, Kesavan MS, Martinez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994; 151(12): 1819–1821.
48. Chakos MH, Mayerhoff DI, Loebel AD, Alvir JM, and Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992; 28(1): 81–86.
49. Sachdev PS. Neuroleptic-induced movement disorders: An overview. Psychiatr Clin North Am 2005; 28(1): 255–74, x.
50. Jhee SS, Zarotsky V, Mohapat SM, Yones CL, and Sims SJ. Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol. Ann Pharmacother 2003; 37(10): 1434–1437.
51. Jamal Omid S, Fernandez BacaVaca G, Lacuey N, et al. Episodic gaze deviation in multiple sclerosis: Versive seizures or oculogyric crises? J Clin Neurosci 2018; 58: 201–203.
52. Tianyi F-L, Agbor VN, and Njim T. Metoclopramide induced acute dystonic reaction: A case report. BMC Res Notes 2017; 10(1): 32.
53. Cheng K-J, Yeh T-C, Ku S-C, Tseng YT, and Liang C-S. Electroconvulsive therapy for anticholinergic and benzodiazepine non-responsive tardive oculogyric crisis: A case report. Am J Ther 2020; 27: e412–e413.
54. Zurowski M, McDonald WM, Fox S, and Marsh L. Psychiatric comorbidities in dystonia: Emerging concepts. Mov Disord 2013; 28(7): 914–920.
55. Das S and Agrawal A. Lurasidone-induced oculogyric crisis. Indian J Psychol Med 2017; 39(5): 719–720.
56. Wagle Shukla A, Brown R, Heese K, et al. High rates of fatigue and sleep disturbances in dystonia. Int J Neurosci 2016; 126(10): 928–935.
57. Skokou M, Tsermpani E-E, Giamarellou A, Gogos A, and Gouris P. Tardive dystonia due to D2 antagonists and other agents. Dystonia - Differ Prospects [Internet] 2018 [cited Apr 24, 2020], https://www.intechopen.com/books/dystonia-different-prospects/tardive-dystonia-due-to-d2-antagonists-and-other-agents (accessed July 27, 2020).